sur Moderna, Inc. (NASDAQ:MRNA)
Moderna Gains European Approval for New COVID-19 Vaccine
Moderna, Inc. has received approval from the European Commission for its updated COVID-19 vaccine, Spikevax®, targeting the SARS-CoV-2 variant LP.8.1. This authorization is relevant for individuals aged six months and older, encompassing all 27 EU member states, Iceland, Liechtenstein, and Norway.
The approval follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Moderna plans to distribute doses in time for the 2025-2026 vaccination season, aligning with guidance from global health authorities recommending updates to address circulating strains.
Moderna's vaccine has generally been well-tolerated, with common adverse reactions including pain at the injection site, headache, fatigue, and chills. Additional regulatory reviews are ongoing worldwide.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Moderna, Inc.